SEAGULL HEALTH
Your health,We care!
Chidamide is China’s first original innovative antineoplastic drug to achieve overseas licensing, and its core advantages lie in innovation, clinical value and medication convenience.
AuthenticGuaranteeFast DeliveryPrivacy On December 23, 2014, the China Food and Drug Administration (CFDA) approved
chidamide for the treatment of patients with relapsed or refractory peripheral
T-cell lymphoma (PTCL) who had received at least one prior systemic
chemotherapy.
On November 29, 2019, the National Medical Products Administration (NMPA) of
China approved chidamide in combination with aromatase inhibitors for the
treatment of postmenopausal patients with estrogen receptor-positive (ER+),
human epidermal growth factor receptor 2-negative (HER2-) locally advanced or
metastatic breast cancer, who had experienced disease recurrence or progression
following endocrine therapy.
On April 30, 2024, the National Medical Products Administration (NMPA) of
China approved chidamide in combination with the R-CHOP regimen (Rituximab,
Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) for the treatment of
previously untreated patients with MYC and BCL2 double-positive diffuse large
B-cell lymphoma (DLBCL).
Shenzhen Chipscreen Biosciences Co., Ltd. announced on April 30, 2024 that chidamide, a self-developed oral subtype-selective histone deacetylase (HDA···【Read More】
Update: 03 Feb,2026Source: Haiou HealthViews: 120
On November 29, 2019, Chidamide (trade name: Epidaza), a first-in-class molecular entity independently developed by Shenzhen Chipscreen Biosciences Co···【Read More】
Update: 03 Feb,2026Source: Haiou HealthViews: 129
Copyright 2024 @ haiouhealth.com All right reserved Seagull health | Bigbear Pharmaceutical | Lucius Pharmaceuticals | 老挝全球药房
